ArticleACS omega2026
Development and Optimization of a Quantum Dot-Based Lateral Flow Assay for Hepatitis B Surface Antigen Detection.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early detection of hepatitis B virus (HBV) is essential for effective disease management, particularly in cases involving low viral loads where timely intervention can prevent chronic progression and liver-related complications. Although enzyme-linked immunosorbent assay (ELISA) and polymerase chain reaction (PCR) are considered the gold standards for HBV detection, their reliance on specialized infrastructure limits their accessibility in resource-limited settings. This study reports the development and optimization of a cadmium quantum dots-based lateral flow assay (cadmiumQDs-LFA) for the detection of hepatitis B surface antigen (HBsAg), harnessing the superior fluorescence properties of cadmiumQDs to improve analytical performance. Compared to conventional gold nanoparticles (AuNPs)-based LFA, cadmiumQDs exhibit higher fluorescence intensity and stability, enabling improved sensitivity for detecting low-abundance biomarkers. Commercially sourced cadmiumQDs were functionalized with mercaptopropionic acid (MPA) to introduce carboxyl (-COOH) functional groups for bioconjugation. The optimized cadmiumQDs conjugates were integrated into an LFA, achieving a limit of detection (LOD) of 15.6 ng/mL for HBsAg. Performance evaluation using 244 clinical serum samples yielded a sensitivity of 86.5%, specificity of 95.9%, positive predictive value (PPV) of 98% and negative predictive value (NPV) of 75.3%. Comparative analysis with a commercial LFA demonstrated enhanced detection of low HBsAg levels, addressing a key limitation of conventional methods.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.